228 related articles for article (PubMed ID: 12698860)
1. King of the pill. Pfizer is the biggest drug company ever. Can it become the best?
Simons J
Fortune; 2003 Apr; 147(7):94-6, 100, 102. PubMed ID: 12698860
[No Abstract] [Full Text] [Related]
2. Pfizer swallows Wyeth, validates niche buster.
Sheridan C
Nat Biotechnol; 2009 Mar; 27(3):218-9. PubMed ID: 19270661
[No Abstract] [Full Text] [Related]
3. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
4. The drug approval process at the Food and Drug Administration. New biotechnology as a paradigm of a science-based activist approach.
Miller HI; Young FE
Arch Intern Med; 1989 Mar; 149(3):655-7. PubMed ID: 2645844
[No Abstract] [Full Text] [Related]
5. Trials and error.
Jacobs T
Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
[No Abstract] [Full Text] [Related]
6. Millennium mergers bring pipeline.
Dove A
Nat Biotechnol; 1999 Dec; 17(12):1151. PubMed ID: 10585700
[No Abstract] [Full Text] [Related]
7. Investing in risk management.
Fiscus PW
Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
[No Abstract] [Full Text] [Related]
8. Biotechnology and patent term extension issues.
Raines L
Food Drug Law J; 1999; 54(2):237-40. PubMed ID: 11758579
[No Abstract] [Full Text] [Related]
9. Innovation and compliance are not diametrically opposed.
Raab GK
Qual Assur; 1994 Mar; 3(1):2-8. PubMed ID: 7804614
[No Abstract] [Full Text] [Related]
10. Shared responsibility in clinical research.
Nightingale SL
Circulation; 1985 Aug; 72(2 Pt 2):I25-30. PubMed ID: 3891137
[No Abstract] [Full Text] [Related]
11. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1983 Feb; 3(1):47-8. PubMed ID: 6680403
[No Abstract] [Full Text] [Related]
12. Leading biotechnology companies quit the IBA.
Gershon D
Nature; 1990 Apr; 344(6266):481. PubMed ID: 2320118
[No Abstract] [Full Text] [Related]
13. Macro trends in pharmaceutical innovation.
Cohen FJ
Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
15. Update of FDA's Critical Path Initiative.
Khleif S
Clin Adv Hematol Oncol; 2009 Mar; 7(3):173-4. PubMed ID: 19398939
[No Abstract] [Full Text] [Related]
16. Reexamining the research exemption.
Flores MA; Campbell C
Nat Biotechnol; 2005 Jun; 23(6):659-61. PubMed ID: 15940230
[No Abstract] [Full Text] [Related]
17. Biotech industry struggles with generics approval.
Knight J
Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
[No Abstract] [Full Text] [Related]
18. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
19. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
20. Big Pharma's Commedia.
Steele FR
Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
[No Abstract] [Full Text] [Related]
[Next] [New Search]
